Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: Potential adhesion molecules in synovial inflammation?

Annals of the New York Academy of Sciences

Volumn 1108, Issue , 2007, Pages 359-371

  Szekanecz, Éva ^a   Śandor, Zsuzsa ^a   Antal Szalmás, Péter ^a   Soós, Lilla ^a   Lakos, Gabriella ^a   Besenyei, Timea ^a   Szentpétery, Ágnes ^a   Simkovics, Enikö ^a   Szántó, János ^a   Kiss, Emese ^a   Koch, Alisa E ^b   Szekanecz, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Anti CCP antibody; rheumatoid factor; Carcinoembryonic antigen; Rheumatoid arthritis; Tumor antigens

Indexed keywords

C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; NEURON SPECIFIC ENOLASE; PROTEIN ANTIBODY; RHEUMATOID FACTOR; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; CELL ADHESION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DISEASE MARKER; FEMALE; HUMAN; IMMUNOASSAY; INFLAMMATORY CELL; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN MOTIF; RHEUMATOID ARTHRITIS; SCLERODERMA; SIALYLATION; SJOEGREN SYNDROME; SYNOVITIS; SYNOVIUM;

EID: 34948855370     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1422.037     Document Type: Conference Paper

References (33)

1. HARRIS, E.D., JR. 1991. Rheumatoid arthritis: pathophysiology and implications for therapy. N. Engl. J. Med. 332: 1277-1287.
2. VISSER, H., L.B. GELINCK, A.H. KAMPFRAATH, et al. 1996. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assay in rheumatoid arthritis. Ann. Rheum. Dis. 55: 157-161.
3. PEPYS, M.B. 1983. C-reactive protein: the role of an ancient protein in modern rheumatology. Clin. Exp. Rheumatol. 1: 3-7.
4. SCHELLENKENS, G.A., B.A.W. DE JONG, F.H.J. VAN DEN HOOGEN, et al. 1998. Citrulline is an essential constituent of antigenic determinants recognised by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 101: 273-281.
5. MEDIWAKE, R., D.A. ISENBERG, G.A. SCHELLEKENS & W.J. VAN VENROOIJ. 2001. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann. Rheum. Dis. 60: 67-68.
6. FORSIND, K., M. AHLMÉN, K. EBERHARDT, et al. 2004. Prediction of radiological outcome in early rheumatoid arthritis in a clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann. Rheum. Dis. 63: 1090-1095.
7. ZENG, X., M. AI, X. TIAN, et al. 2003. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J. Rheumatol. 30: 1451-1455.
8. BONGI, S.M., R. MANETTI, D. MELCHIORRE, et al. 2004. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity 37: 495-501.
9. SZEKANECZ, Z., G.K. HAINES, L.A. HARLOW, et al. 1995. Increased synovial expression of the adhesion molecules CD66a, CD66b and CD31 in rheumatoid and osteoarthritis. Clin. Immunol. Immunopathol. 76: 180-186.
10. CANTAGREL, A., L. MOULINIER, K. BELJIO, et al. 1994. Increase of CA 19.9 in dysimmune inflammatory rheumatism. Apropos of 6 cases. Rev. Rhum. Ed. Fr. 61: 599-606.
11. RUMP, A., Y. MORIKAWA, M. TANAKA, et al. 2004. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 279: 9190-9198.
12. DUFFY, M.J., S. SHERING, F. SHERRY, et al. 2000. CA 15-3, a prognostic marker in breast cancer. Int. J. Biol. Markers 15: 330-333.
13. WILLIAMS, A.F. & A.N. BARCLAY. 1988. The immunoglobulin superfamily. Domains for cell surface recognition. Annu. Rev. Immunol. 6: 381-405.
14. LANCE, M.P. 1990. CEA as a cell adhesion molecule. Gastroenterology 99: 277-278.
15. KUIJPERS, T.W., M. HOOGERWERF, L.J. VAN DER LAAN, et al. 1992. CD66 nonspecific cross-reacting antigens are involved in neutrophil adherence to cytokine-activated endothelial cells. J. Cell. Biol. 118: 457-466.
16. STOCKS, S.C. & M.A. KERR. 1992. Neutrophil NCA-160 (CD66) is the major protein carrier of selectin binding carbohydrate groups LewisX and sialyl lewisX. Biochem. Biophys. Res. Commun. 195: 478-483.
17. AUDETTE, M., F. BUCHEGGER, M. SCHREYER & J.P. MACH. 1987. Monoclonal antibody against carcinoembryonic antigen (CEA) identifies two new forms of crossreacting antigens of molecular weights 90,000 and 160,000 in normal granulocytes. Mol. Immunol. 24: 1177-1186.
18. DUCKER, T.P. & K.M. SKUBITZ. 1992. Subcellular localization of CD66, CD67, and NCA in human neutrophils. J. Leuk. Biol. 52: 11-16.
19. TORSTEINSDOTTIR, I., N.G. ARVIDSON, R. HALLGREN & L. HAKANSSON. 1999. Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis and the effect of glucocorticoids. Scand. J. Immunol. 50: 433-439.
20. BENCHIMOL, S., A. FUKS, S. JOTHY, et al. 1989. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57: 327-334.
21. UNGER, A., G.S. PANAYI & M.H. LESSOF. 1975. Carcinoembryonic antigen in rheumatic diseases. Rheumatol. Rehabil. 14: 19-24.
22. SHIMOMURA, C., K. EGUCHI, A. KAWAKAMI, et al. 1989. Elevation of tumor associated antigen CA 19-9 levels in patients with rheumatic diseases. J. Rheumatol. 16: 1410-1415.
23. KIMURA, K., K. EZOE, H. YOKOZEKI, et al. 1995. Elevated serum CA125 in progressive systemic sclerosis with pleural effusion. J. Dermatol. 22: 28-31.
24. VALERIO-MARZANO, A., A. MORABITO, E. BERTI & R. CAPUTO. 1998. Elevated circulating CA 15.3 levels in a subset of systemic sclerosis with severe lung involvement. Arch. Dermatol. 34: 645.
25. TAKEDA, N., H. IHN & S. TERAMOTO. 2001. Markedly increased levels of IL-6 and CA125 in pleural fluids of an elderly person with overlap syndrome of systemic sclerosis and systemic lupus erythematosus. Age Ageing 30: 171.
26. SAFADI, R., M. LIGUMSKY, E. GOLDIN, et al. 1998. Increased serum CA 19-9 antibodies in Sjögren's syndrome. Postgrad. Med. J. 74: 543-544.
27. FABRIS, C., E. FALLETI, M. PIRISI, et al. 1995. Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease associated with increased circulating levels of adhesion molecules. Clin. Chim. Acta 243: 25-33.
28. RAHN, J.J., J.W. CHOW, G.J. HORNE, et al. 2005. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin. Exp. Metastasis 22: 475-483.
29. DETTKE, M., G. PALFI, E. PURSCH, et al. 2001. Increased expression of the blood group-related Lewis-Y antigen on synovial fluid granulocytes of patients with arthritic joint diseases. Rheumatology 40: 1033-1077.
30. HALLORAN, M.M., W.W. CARLEY, P.J. POLVERINI, et al. 2000. Ley/H: an endothelial-selective, cytokine-inducible angiogenic mediator. J. Immunol. 164: 4868-4877.
31. KOCH, A.E., J.C. BURROWS, G.K. HAINES, et al. 1991. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest. 64: 313-320.
32. SEELENMEYER, C., S. WEGEHINGEL, J. LECHNER & W. NICKEL. 2003. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J. Cell. Sci. 116: 1305-1318.
33. CORREA, I., T. PLUNKETT, A. VLAD, et al. 2003. Formand pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T cell migration. Immunology 108: 32-41.